Did You Know...
...that after Parker Brothers executives turned down the game of Monopoly because it had "52 fundamental errors" (including taking too long to play), a copy of the game wound up in the home of the company president who stayed up until 1 a.m. to finish playing it? He was so impressed by the game that the next day he wrote to inventor Charles Darrow and offered to buy it!
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8173683 | Methods for treating cognitive disorders Disclosed herein are methods of treating a patient suffering a cognitive disorder. ... | 05/08/2012 |
| 8168631 | 3-(4-fluorophenyl)-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic activity Compounds according to the formula below are disclosed herein: Therapeutic methods, compositions, and medicaments related thereto are also disclosed. ... | 05/01/2012 |
| 8153666 | Compounds having analgesic and/or immunostimulant activity The compounds shown by their structural formulas in the specification have analgesic and or immunostimulant activity in mammals. ... | 04/10/2012 |
| 8153645 | Treating pain using selective antagonists of persistent sodium current The present invention provides methods of treating chronic pain in a mammal by administering to the mammal an effective amount of a selective persistent sodium channel antagonist that has at least 20-fold selectivity for persistent sodium current relative to transie... | 04/10/2012 |
| 8147865 | Steroid-containing sustained release intraocular implants and related methods Biocompatible intraocular implants include a steroid and an auxiliary agent, where the auxiliary agent is present in an amount sufficient to lessen the severity of at least one side effect compared to the use of an otherwise identical implant lacking said auxiliary ... | 04/03/2012 |
| 8143410 | Kinase inhibitors The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination wit... | 03/27/2012 |
| 8124612 | Treating neurological disorders using selective antagonists of persistent sodium current The present invention provides methods of treating neurological disorders in a mammal by administering to the mammal an effective amount of a selective persistent sodium channel antagonist that has at least 20-fold selectivity for persistent sodium current relative ... | 02/28/2012 |
| 8119154 | Sustained release intraocular implants and related methods Biocompatible intraocular implants include a steroid and a polymer associated with each other to facilitate release of the steroid into an eye for a period of time greater than about two months. The steroid may be associated with a biodegradable polymer matrix, such... | 02/21/2012 |
| 8088407 | Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor Methods for reducing or preventing transplant rejection in the eye of an individual are described, comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a b... | 01/03/2012 |
| 8071120 | Methods for treating neovascularization and intravitreal implants Methods for reducing or preventing transplant rejection in the eye of an individual are described, comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a b... | 12/06/2011 |
| 8063031 | Implants and methods for treating inflammation-mediated conditions of the eye Methods for treating inflammation-mediated conditions of the eye are described, comprising: implanting into the vitreous of the eye of an individual a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, wherein the implant d... | 11/22/2011 |
| 8062657 | Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component that includes an Glucocorticoid Derivative which, upon delivery to the posterior segment of a mammalian eye, does not si... | 11/22/2011 |
| 8048445 | Ocular implant made by a double extrusion process The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocu... | 11/01/2011 |
| 8043628 | Methods for reducing edema Methods for reducing or preventing neovascularization or edema in the eye by implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer. ... | 10/25/2011 |
| 8039010 | Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier A biocompatible, sustained release intraocular drug delivery system comprising a protein or polynucleotide therapeutic agent, a polymeric carrier for the therapeutic agent and a long chain fatty alcohol release modifier. The biocompatible, sustained release intraocu... | 10/18/2011 |
| 8034370 | Ocular implant made by a double extrusion process The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocu... | 10/11/2011 |
| 8034366 | Ocular implant made by a double extrusion process The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocu... | 10/11/2011 |
| 8013000 | 3-heteroaryl-3-hydroxy-2-amino-propyl amines and related compounds having analgesic and/or immuno stimlant activity Compounds of the formula where the variables have the meaning defined in the specification have analgesic and/or immunostimulant effect in mammals. ... | 09/06/2011 |
| 7993634 | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods Biocompatible intraocular implants, such as microparticles, include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be a... | 08/09/2011 |
| 7977351 | Heteroaryl dihydroindolones as kinase inhibitors The present invention provides a compound represented by the formula: wherein the variables R1, b, R6, Y, Z, X, R and a are defined in the specification. Said compound may be used in a method f... | 07/12/2011 |
| 7977335 | Methods of preventing and reducing the severity of stress-associated conditions The present invention provides a method of preventing or reducing the severity of a stress-associated condition in a subject by systemically administering to the subject an effective amount of brimonidine or a pharmaceutically acceptable salt, ester, amide, stereois... | 07/12/2011 |
| 7968711 | Abnormal cannabidiols as agents for lowering intraocular pressure The present invention provides a method of treating glaucoma or ocular hypertension which comprises applying to the eye of a person in need thereof an amount sufficient to treat glaucoma or ocular hypertension of a compound of formula I | 06/28/2011 |
| 7964191 | Compositions and methods for the treatment of ophthalmic disease Compositions and methods of treating ocular disorders comprising CXCR4 inhibitory compositions. ... | 06/21/2011 |
| 7931909 | Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component which includes an alpha 2 adrenergic receptor agonist that is cleared from the anterior segment of an individual's eye t... | 04/26/2011 |
| 7915443 | Sulfoximines as kinase inhibitors The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. ... | 03/29/2011 |
| 7902251 | Method for treating pain The present invention provides pharmaceutical compositions useful in a method for treating neuropathic pain, said method comprising administration of a pain-ameliorating effective amount of the compound according to formula I | 03/08/2011 |
| 7902155 | Therapeutic methods using cyclosporine components Methods of treating humans or animals having dysfunctional oral mucosal tissue are disclosed which include topically administering cyclosporine A, salts thereof and/or mixtures thereof in an oral cavity of the human or animal. ... | 03/08/2011 |
| 7884115 | Methods and compositions for the treatment of pain and other neurological conditions Methods and compositions for the treatment of conditions including stress-associated, chronic pain, and neurodegenerative conditions in a mammal using a composition comprising NB-DNJ or a compound structurally similar thereto. ... | 02/08/2011 |
| 7833966 | Enhanced ocular neuroprotection and neurostimulation Use of topically applied cyclosporine to enhance corneal sensitivity restoration rate in an eye of an individual after ocular surgery such as laser-assisted in situ keratomileusis (LASIK) in which nerves are severed. ... | 11/16/2010 |
| 7815917 | Botulinum neurotoxin serotype B activatable Botulinum neurotoxin serotype Bs The specification discloses modified Clostridial toxins comprising a Clostridial toxin substrate cleavage site located within the di-chain loop region; polynucleotide molecules encoding such modified Clostridial toxins comprising a Clostridial toxin substrate cleava... | 10/19/2010 |
| 7780968 | Clostridial toxin derivatives and methods for treating pain Agents for treating pain, methods for producing the agents and methods for treating pain by administration to a patient of a therapeutically effective amount of the agent. The agent can include a clostridial neurotoxin, or a component or fragment or derivative there... | 08/24/2010 |
| 7767718 | Treating pain using selective antagonists of persistent sodium current The present invention provides methods of treating chronic pain in a mammal by administering to the mammal an effective amount of a selective persistent sodium channel antagonist that has at least 20-fold selectivity for persistent sodium current relative to transie... | 08/03/2010 |
| 7763651 | Treating pain using selective antagonists of persistent sodium current The present invention provides methods of treating chronic pain in a mammal by administering to the mammal an effective amount of a selective persistent sodium channel antagonist that has at least 20-fold selectivity for persistent sodium current relative to transie... | 07/27/2010 |
| 7754440 | High-throughput screen for identifying selective persistent sodium channels channel blockers A method for identifying a selective persistent Na+ channel blocker by measuring the ability of the blocker to reduce or inhibit a persistent Na+ current to a greater degree than a transient Na+ current. Aspects of the present method... | 07/13/2010 |
| 7749759 | Cell compositions useful for cell-based FRET assays for clostridial toxins The present invention provides a method of determining clostridial toxin activity by (a) contacting with a sample a cell containing a clostridial toxin substrate that includes a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission sp... | 07/06/2010 |
| 7749514 | Activatable clostridial toxins Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids. ... | 07/06/2010 |
| 7745400 | Prevention and treatment of ocular side effects with a cyclosporin Presently described are methods of administration and associated treatment of one or more ocular conditions using cyclosporine, or an analog or derivative thereof. The ocular conditions can be a result of treatment using other therapeutic agents, such as chemotherap... | 06/29/2010 |
| 7740868 | Activatable clostridial toxins Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids. ... | 06/22/2010 |
| 7736659 | Clostridial toxin derivatives and methods for treating pain Agents for treating pain, methods for producing the agents and methods for treating pain by administration to a patient of a therapeutically effective amount of the agent. The agent can include a clostridial neurotoxin, or a component or fragment or derivative there... | 06/15/2010 |
| 7728034 | Treating neurological disorders using selective antagonists of persistent sodium current The present invention provides methods of treating neurological disorders in a mammal by administering to the mammal an effective amount of a selective persistent sodium channel antagonist that has at least 20-fold selectivity for persistent sodium current relative ... | 06/01/2010 |
